Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- May 24, 2024 Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
- May 14, 2024 Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
- May 7, 2024 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
- May 6, 2024 Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
- May 1, 2024 Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- April 26, 2024 Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
- April 23, 2024 Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
- April 4, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- April 1, 2024 Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- March 11, 2024 Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
Displaying 21 - 30 of 303